A STABILITY, ACCURACY, AND ROBUSTNESS REPRESENTING LIQUID CHROMATOGRAPHIC METHOD FOR THE QUANTIFICATION OF ZANUBRUTINIB AND ITS SPECIFIED IMPURITIES

SUBHASHINI KANTHETI; R. RAMESH RAJU

doi:10.22159/ijap.2023v15i5.48213

Authors

SUBHASHINI KANTHETI Department of PG Chemistry, Akkineni Nageswara Rao College, Gudivada-521301, India https://orcid.org/0009-0004-2367-753X
R. RAMESH RAJU Department of Chemistry, Acharya Nagarjuna University, Nagarjuna Naga, Andhra Pradesh, India

DOI:

https://doi.org/10.22159/ijap.2023v15i5.48213

Keywords:

Zanubrutinib, Specified impurities, Linearity recovery, and robustness

Abstract

Objective: An innovative RP-HPLC isocratic method was established and then validated using Zanubrutinib and its specified impurities (Impurity-1, Impurity-2, Impurity-3, Impurity-4, and Impurity-5).

Methods: In this method, effective chromatographic separation was given an X-Bridge Phenyl column measuring 250 mm x 4.6 mm, packed column with 5μ as a particle size. Acetonitrile, 1% Ortho Phosphoric acid (pH: 2.7), and methanol in the volume ratios 40, 40, and 20 were utilized as a mobile phase at room temperature with an optimized 1.0 ml/min flow rate. Wavelength was detected at 225 nm by using a PDA detector.

Results: Retention times of zanubrutinib and its specified impurities were recorded at 13.284, 4.730, 6.816, 9.583, 10.726, and 12.287. Moreover, other parameters USP tailing is good, USP plate count above 4000, and USP resolution is greater than are equal to 2. The Obtained peaks are homogeneous, hence the purity angle is less than the purity threshold and No Purity Flag. According to ICH guidelines, this method was validated. Zanubrutinib (5-75 µg/ml), their quantified impurity-1, impurity-2, impurity-4, impurity-5 (0.1-1.5 µg/ml), and impurity-3 (0.1-1.5 µg/ml) are proved through linearity method in between LOQ to 75 quantified levels. The % recovery was present between 100.18-95.85, 103.15-93.80, which is a good and acceptance range (amongst 85% and 115%) for drug and specified impurities. The limit of quantitation (LOQ) and limit of detection (LOD) values were assessed for zanubrutinib and its specified impurities were tabulated. These values were calculated using slope (σ) and standard deviation (SD) methods. Method precision (M. P.) and Intermediate (I. P.) Intermediate (I. P.) precision was estimated by evaluating several (six) samples of a similar batch as per the planned technique on the day and the next day, using different columns and systems. Robustness information significantly affects the resolution between Zanubrutinib and specified impurities. The remaining parameters do not impact the parameter’s system suitability.

Conclusion: Hence this method was chosen for common analysis. Finally, the system-suitable parameters and validation parameters values are acceptable limits.

Downloads

Download data is not yet available.

References

Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57. doi: 10.1186/s12943-018-0779-z, PMID 29455639.

Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka Stryczynska K, Willmer J. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N Engl J Med. 2019;380(25):2406-17. doi: 10.1056/NEJMoa1901981. PMID 31075187.

Matsushita M, Yamadori T, Kato S, Takemoto Y, Inazawa J, Baba Y. Identification and characterization of a novel SH3-domain binding protein, Sab, which preferentially associates with Bruton’s tyrosine kinase (BtK). Biochem Biophys Res Commun. 1998;245(2):337-43. doi: 10.1006/bbrc.1998.8420, PMID 9571151.

FDA grants accelerated approval to zanubrutinib for mantle cell lymphoma. United States Food and Drug Administration (FDA). Archived from the original on. This article incorporates text from this source, which is in the public domain; Nov 15 2019.

Li G, Liu X, Chen X. Simultaneous development of zanubrutinib in the USA and China. Nat Rev Clin Oncol. 2020;17(10):589-90. doi: 10.1038/s41571-020-0414-y, PMID 32651571.

Atallah E, Wijayasiri P, Cianci N, Abdullah K, Mukherjee A, Aithal GP. Zanubrutinib-induced liver injury: a case report and literature review. BMC Gastroenterol. 2021;21(1):244. doi: 10.1186/s12876-021-01825-2, PMID 34051727.

Skarbnik AP, Goy AH. Mantle cell lymphoma: state of the art. Clin Adv Hematol Oncol. 2015;13(1):44-55. PMID 25679973.

Ye H, Desai A, Zeng D, Romaguera J, Wang ML. Frontline treatment for older patients with mantle cell lymphoma. Oncologist. 2018;23(11):1337-48. doi: 10.1634/theoncologist.2017-0470, PMID 29895632.

Ye H, Desai A, Huang S, Jung D, Champlin R, Zeng D. Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy. J Exp Clin Cancer Res. 2018;37(1):150. doi: 10.1186/s13046-018-0800-9, PMID 30005678.

Syed YY. Zanubrutinib: first approval. Drugs. 2020;80(1):91-7. doi: 10.1007/s40265-019-01252-4, PMID 31933167.

Sawalha Y, Bond DA, Alinari L. Evaluating the therapeutic potential of zanubrutinib in the treatment of relapsed/refractory mantle cell lymphoma: evidence to date. Onco Targets Ther. 2020;13:6573-81. doi: 10.2147/OTT.S238832. PMID 32753893.

Product information Zanubrutinib Item No. 28924 Cayman Chemicals; 2019.

Hong M, Lee T, Young Kang SY, Kim SJ, Kim W, Ko YH. Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior. Mod Pathol. 2016 May 1;29(5):430-43. doi: 10.1038/modpathol.2016.47, PMID 27015135.

Bachanova V, Miller JS. NK cells in therapy of cancer. Crit Rev Oncog. 2014;19(1-2):133-41. doi: 10.1615/CritRevOncog.2014011091, PMID 24941379.

Hanne M, Hawken SJ. Metaphors for illness in contemporary media. Med Humanit. 2007;33(2):93-9. doi: 10.1136/jmh.2006.000253, PMID 23674429.

McWhinney IR. Health and disease: problems of definition. CMAJ. 1987;136(8):815. PMID 3567791.

Johnson RW. The concept of sickness behavior: a brief chronological account of four key discoveries. Vet Immunol Immunopathol. 2002;87(3-4):443-50. doi: 10.1016/S0165-2427(02)00069-7, PMID 12072271.

Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021;5(12):2577-85. doi: 10.1182/bloodadvances.2020004074, PMID 34152395.

Sawalha Y, Bond DA, Alinari L. Evaluating the therapeutic potential of zanubrutinib in the treatment of relapsed/refractory mantle cell lymphoma: evidence to date. Onco Targets Ther. 2020;13:6573-81. doi: 10.2147/OTT.S238832. PMID 32753893.

Rhodes JM, Mato AR. Zanubrutinib (BGB-3111), a second-generation selective covalent inhibitor of Bruton’s tyrosine kinase and its utility in treating chronic lymphocytic leukemia. Drug Des Devel Ther. 2021;15:919-26. doi: 10.2147/DDDT.S250823, PMID 33688166.

Dreyling M, Tam CS, Wang M, Smith SD, Ladetto M, Huang H. A phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncol. 2021;17(3):255-62. doi: 10.2217/fon-2020-0794, PMID 32985902.

Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton’s tyrosine kinase. J Med Chem. 2019;62(17):7923-40. doi: 10.1021/acs.jmedchem.9b00687, PMID 31381333.

Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H. Treatment of patients with relapsed or refractory mantle–cell lymphoma with zanubrutinib, a selective inhibitor of Bruton’s tyrosine Kinase Zanubrutinib for relapsed/refractory MCL. Clin Cancer Res. 2020;26(16):4216-24. doi: 10.1158/1078-0432. CCR-19-3703.

Vijayakumari M, Ch BR. Stability indicating validated hplc method for the determination of zanubrutinib in bulk and pharmaceutical dosage form. Asian J Pharm Clin Res. 2020;13:159-62. doi: 10.22159/ajpcr.2020.v13i10.38621.

Christen D, Griffiths JH, Sheridan J. The microwave spectrum of imidazole; complete structure and the electron distribution from nuclear quadrupole coupling tensors and dipole moment orientation. Z Naturforsch A. 1981;36(12):1378-85. doi: 10.1515/zna-1981-1220.

Stout SJ, DaCunha AR. Tuning and calibration in thermospray liquid chromatography/mass spectrometry using trifluoroacetic acid cluster ions. Anal Chem. 1989;61(18):2126-8. doi: 10.1021/ac00193a027.

Alston Steiner PA, Gordy W. Precision measurement of dipole moments and other spectral constants of normal and deuterated methyl fluoride and methyl cyanide. J Mol Spectrosc. 1966;21(1-4):291-301. doi: 10.1016/0022-2852(66)90152-4.

International conferences of harmonization validation of analytical procedures test and methodology. Vol. Q2(R1); 2005. Available from: http://www.ich.org.

Sethi PD. HPLC quantitative analysis of pharmaceutical formulations. India: CBS Publications; 2001.

Shalini K, Ilango K. Development, evaluation and RP-HPLC method for simultaneous estimation of quercetin, ellagic acid and kaempferol in a polyherbal formulation. Int J App Pharm. 2021;13:183-92. doi: 10.22159/ijap.2021v13i3.41028.

Kishore VNV, Ramana GV. Simultaneous determination of tigecycline and its potential impurities by a stability-indicating Rp-HPLC-UV detection technique. Int J App Pharm. 2022;14(1):75-82. doi: 10.22159/ijap.2022v14i1.41243.

Gorumutchu GP, Ratnakaram VN. Determination of mianserin using tropaeolin-ooo by ion pair formation. Int J App Pharm. 2019;11(1):168-73. doi: 10.22159/ijap.2019v11i1.30125.